Turn Therapeutics ($TTRX) to Ring the Closing Bell at Nasdaq

About

About
Turn Therapeutics

Our mission is to increase access to effective medicines for high need populations.

Our Team

Leadership and Vision

Turn Therapeutics was founded by Bradley Burnam, Chief Executive Officer, whose experience navigating FDA pathways and building regulated products informs the company’s execution-driven culture.

Under his leadership, Turn Therapeutics is advancing a clear thesis: The future of medicine lies in targeted therapies that work locally, deliver meaningful efficacy, and reduce unnecessary systemic exposure.

Out of that necessity to survive came the foundation of Turn Therapeutics: a company with three FDA cleared medical devices, 15+ patents, and a robust drug pipeline.

Now, Turn Therapeutics is focused on advancing its therapies and mission to increase access to safe and effective medicines.

Our Team

Dr. Neil Ghodadra, MD

Chief Medical Officer, Board Director

Read Bio

Zuraiz Chaudhary, CPA

Chief Accounting Officer, VP Finance

Read Bio

Muhammad Zubair

Controller

Read Bio

Arthur Golden

Board Director

Read Bio

Andrew Gengos

Board Director

Read Bio

Kent Kester, MD

Board Director

Read Bio

Martin Dewhurst

Board Director

Read Bio

Dr. Neil Ghodadra, MD

Chief Medical Officer, Board Director

Dr. Neil Ghodadra, Board Certified Orthopedic Surgeon, joined Turn in Q3 2017. Renowned for surgical skill and orthopedic research, he graduated Magna Cum Laude from Duke University with a BS in Biology, and with Honors from Duke Medical School. His residency at Rush Medical Center focused on sports medicine, specializing in knee & shoulder surgery.

Linkedin

Zuraiz Chaudhary, CPA

Chief Accounting Officer, VP Finance

Zuraiz, VP of Finance and Chief Accounting Officer, is a seasoned finance & accounting executive with more than a decade experience in working with PwC, EY and KPMG.  Zuraiz is a licensed CPA in California and Texas, has a bachelor’s in business administration from Asia-e University (Malaysia), is a member of the Institute of Chartered Accountants of Pakistan. Zuraiz specializes in financial reporting, SOX compliance and internal controls.

Linkedin

Muhammad Zubair

Controller

Zubair, Controller, has 5+ years of accounting and finance management experience in companies ranging from medium-sized companies to pulicly traded multinationals. Zubair is a member of the Institute of Chartered Accountants of Pakistan and holds a Master’s degree in accounting & finance (Equivalent). 

Linkedin

Arthur Golden

Outside Counsel, Board Director

Arthur Golden is a 41-year partner of Davis Polk’s M&A practice, former co-chair of the dept. & 9-year member of the firm’s Management Committee. As Emerson Electric’s senior independent board member, he chairs the Finance Committee. Known for multinational acquisitions and biopharma expertise, Arthur is also the Chair of Rensselaer Polytechnic Institute’s Board of Trustees.

Linkedin

Andrew Gengos

Board Director

Andrew Gengos is a seasoned finance & strategy exec with 30+ years in life sciences and biotech. Former CBO at Cyteir Therapeutics, he led the company to go public. Andrew served as CEO at ImmunoCellular & Neuraltus, providing strategic direction in oncology & neurodegenerative disease. He’s held CFO/CBO roles at AOBiome, COO at Synlogic, & VP at Amgen.

Linkedin

Kent Kester, MD

Advisor, Board Director

Kent Kester, M.D., is Executive Director of Vaccine R&D at CEPI, overseeing a $1B portfolio. He previously held leadership roles at IAVI, Sanofi Pasteur, and the U.S. Army, where he commanded the Walter Reed Army Institute of Research. Dr. Kester earned his M.D. from Thomas Jefferson University and trained in infectious diseases at Walter Reed.

Linkedin

Martin Dewhurst

Advisor

Martin Dewhurst spent 30 years at McKinsey, leading its life sciences practice and co-founding the McKinsey Health Institute. He has advised across biopharma, medtech, and consumer health, and is a frequent speaker at global conferences. He now advises Lightrock and PJT Partners and serves on multiple boards. Mr. Dewhurst holds degrees from Oxford and INSEAD.

Linkedin
  • Westlake Village, CA
  • 1-818-564-4011

Peter Gould

Advisor

Peter Gould, Managing Director at J.P. Morgan Private Bank, brings over 30 years of experience in asset-based lending, commercial and investment banking, and private banking. Formerly with Wells Fargo’s Abbot Downing, Citibank, and Bank of America, he specializes in complex credit and capital solutions. Peter also serves as Chairman of Interface Children & Family Services and has long been active in community leadership.

Linkedin

Jeffrey Bunder

Advisor

Jeff is a seasoned financial professional with deep expertise in private equity, corporate finance, and transaction advisory. Over two decades at Ernst & Young, he served as Global Private Equity Leader, advising major firms on deals, fundraising, and strategy. His leadership and experience make him a valuable addition to the Turn Therapeutics team.

Linkedin

Bradley Burnam

Chief Executive Officer & Founder

Bradley Burnam, Founder & CEO, developed PermaFusion®, a patented drug delivery system, to combat his hospital-acquired skin infection. This innovation led to Hexagen™ Wound Dressing, Turn’s flagship product. Burnam, a self-taught regulatory and formulation expert, secured Turn’s first three FDA clearances solo before assembling a skilled team.

Linkedin

Subscribe to the Founder's Blog

Enter your information to subscribe for the latest updates from our Founder’s Blog.

Sign Up for Updates

Enter your information to receive the latest product updates and news from Turn Therapeutics.